Abstract
The COVID-19 pandemic has infected over 200 million people worldwide and killed more than 4 million as of August 2021. Many intervention strategies have been utilized by governments around the world, including masks, social distancing, and vaccinations. However, officials making decisions regarding interventions may have a limited time to act. Computer simulations can aid them by predicting future disease outcomes, but they also have limitations due to requirements on processing power or time. This paper examines whether a machine learning model can be trained on a small subset of simulation runs to inexpensively predict future disease trajectories very close to the original simulation results. Using four previously published agent-based models for COVID-19, this paper analyzes the predictions of decision tree regression machine learning models and compares them to the results of the original simulations. The results indicate that accurate machine learning meta-models can be generated from simulation models with no strong interventions (e.g., vaccines, lockdowns) using small amounts of simulation data. However, meta-models for simulation models that include strong interventions required much more training data to achieve a similar accuracy. This indicates that machine learning meta-models could be used in some scenarios to assist in faster decision making.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no financial support for the research or authorship of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable (no human data used).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email Address: lutzcb{at}miamioh.edu
Email Address: giabbapj{at}miamioh.edu
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.